Evidence map›Paper›PMID 41601761›Full record

ReviewFrontiers in medicine2025

Diabetic cardiomyopathy from a gut microbiota perspective: research progress and prospects.

Yuying Liang, Yan Gao, Wei Wang, Zhuo Zhao

Abstract readReview
In one paragraph

Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuying LiangSchool of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, China.
Yan GaoSchool of Qingdao University, Qingdao, Shandong, China.
Wei WangDepartment of Cardiovascular Surgery, Shandong Public Health Clinical Center, Jinan, Shandong, China.
Zhuo ZhaoDepartment of Cardiovascular Medicine, Jinan Central Hospital, Jinan, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent evidence indicates that gut microbiota dysbiosis impairs intestinal barrier function, induces endotoxemia, and consequently triggers systemic inflammatory cascades. Advances in gut microbiota research have further elucidated its critical role in the pathogenesis of diabetes and its complications. This review examines the relationship between diabetic cardiomyopathy and gut microbiota, delineating microbial metabolite-mediated and immunomodulatory influences on myocardial function, while proposing novel therapeutic strategies.

Indexed as

diabetesdiabetic cardiomyopathygut microbiotainflammatorymitochondria dysfunction

Identifiers

PMID41601761
PMCPMC12833025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.